On the face of it, it’s a bizarre concept: the drug industry working as part of a broad-based coalition with patient groups and former government health officials to try to get more money for the Food & Drug Administration.
But what might be more bizarre is that it’s happened twice: since the start of the negotiations surrounding the reauthorization...




